Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.

Giallongo C, La Cava P, Tibullo D, Barbagallo I, Parrinello N, Cupri A, Stagno F, Consoli C, Chiarenza A, Palumbo GA, Di Raimondo F.

BMC Cancer. 2013 Feb 5;13:60. doi: 10.1186/1471-2407-13-60.

2.

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Xu XH, Gan YC, Xu GB, Chen T, Zhou H, Tang JF, Gu Y, Xu F, Xie YY, Zhao XY, Xu RZ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.

3.

[Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].

Wang XD, Qiu L, Lu RZ, Chen LJ, Zhan ZM, Han BH, Zhang BL, Ma J.

Zhonghua Yi Xue Za Zhi. 2007 Dec 25;87(48):3399-405. Chinese.

PMID:
18476538
4.

Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.

Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto JP, Raynaud S, Tartare-Deckert S, Auberger P.

Cancer Res. 2010 Dec 1;70(23):9659-70. doi: 10.1158/0008-5472.CAN-10-2034. Epub 2010 Nov 23.

5.

Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.

Bansal P, Ghalaut VS, Sharma TK, Ghalaut PS, Dokwal S, Ghalaut R, Kulshrestha M, Dahiya K.

Clin Lab. 2014;60(11):1845-52.

PMID:
25648025
6.

The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia.

Du Q, Wang L, Zhu H, Zhang S, Xu L, Zheng W, Liu X.

Med Oncol. 2010 Sep;27(3):673-9. doi: 10.1007/s12032-009-9267-z. Epub 2009 Aug 4.

PMID:
19653139
7.

Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.

Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, Carturan S, Messa E, Morotti A, Giugliano E, Rege-Cambrin G, Alberti D, Baccarani M, Saglio G.

Cancer. 2004 Sep 1;101(5):979-88.

8.

Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.

Wang W, Zhang J, Li Y, Yang X, He Y, Li T, Ren F, Zhang J, Lin R.

Cancer Lett. 2015 Jan 28;356(2 Pt B):791-9. doi: 10.1016/j.canlet.2014.10.033. Epub 2014 Oct 31.

PMID:
25449787
9.

Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.

Wu S, Zheng C, Chen S, Lin B, Chen Y, Zhou W, Li Z.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):367-72. doi: 10.1016/j.bbrc.2014.11.089. Epub 2014 Dec 2.

PMID:
25475722
10.

Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.

Liao HF, Su YC, Zheng ZY, Jhih Cai C, Hou MH, Chao KS, Chen YJ.

Biomed Pharmacother. 2012 Jul;66(5):378-83. doi: 10.1016/j.biopha.2011.12.008. Epub 2012 Feb 16.

PMID:
22397755
11.

Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy.

Ferreira AF, de Oliveira GL, Tognon R, Collassanti MD, Zanichelli MA, Hamerschlak N, de Souza AM, Covas DT, Kashima S, de Castro FA.

Acta Haematol. 2015;133(4):354-64. doi: 10.1159/000369446. Epub 2015 Feb 17.

PMID:
25721555
12.

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.

Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Müller-Brüsselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A.

Leukemia. 2005 Oct;19(10):1774-82.

PMID:
16136169
14.

Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.

Li X, Miao H, Zhang Y, Li W, Li Z, Zhou Y, Zhao L, Guo Q.

Arch Toxicol. 2015 Jan;89(1):121-36. doi: 10.1007/s00204-014-1226-6. Epub 2014 Mar 27.

PMID:
24671465
15.

Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

Casetti L, Martin-Lannerée S, Najjar I, Plo I, Augé S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I.

Cancer Res. 2013 Apr 1;73(7):2052-8. doi: 10.1158/0008-5472.CAN-12-3955. Epub 2013 Feb 11.

16.

Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.

Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.

Clin Cancer Res. 2009 Mar 1;15(5):1686-97. doi: 10.1158/1078-0432.CCR-08-2141. Epub 2009 Feb 24.

17.

Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients.

Ciarcia R, Vitiello MT, Galdiero M, Pacilio C, Iovane V, d'Angelo D, Pagnini D, Caparrotti G, Conti D, Tomei V, Florio S, Giordano A.

J Cell Physiol. 2012 Jun;227(6):2798-803. doi: 10.1002/jcp.23029.

PMID:
21938724
18.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
19.

[Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].

Yang H, Yan JS, Tao R, Hao SG, Liang H, Ma LY.

Zhonghua Zhong Liu Za Zhi. 2012 Mar;34(3):169-75. doi: 10.3760/cma.j.issn.0253-3766.2012.03.003. Chinese.

PMID:
22780968
20.

Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.

Chai JH, Zhang Y, Tan WH, Chng WJ, Li B, Wang X.

BMC Cancer. 2011 Dec 9;11:512. doi: 10.1186/1471-2407-11-512.

Supplemental Content

Support Center